** Shares of Lyell Immunopharma LYEL.O rise 15% to $11.70 premarket
** Co says 88% of patients with a type of blood cancer who were given LYEL's experimental cell therapy, called LYL314, had their tumors shrink or disappear after treatment in an early- to mid-stage trial
** LYEL says 72% of patients experienced a complete disappearance of all signs of their cancer following treatment with the therapy
** Up to last close, stock had fallen 21% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.